Measuring regulatory outcomes

EMA wants to increase the use of real-world evidence and digital health to better understand the impact of pharmacovigilance decisions on patient outcomes.

Pharmacovigilance decisions fall along a broad continuum, from small changes such as reducing the size of a packet of pills or adding a drug-drug interaction to a drug label, to larger decisions such as restricting an indication or withdrawing a drug from the market. ...